Peay Holly L, Henderson Gail E
Department of Clinical Genetics, Leiden University Medical Centre, Leiden, the Netherlands.
Department of Social Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
J Virus Erad. 2015 Jan 1;1(2):51-53. doi: 10.1016/S2055-6640(20)31143-2.
HIV cure research, a diverse set of studies aimed at eradicating or greatly reducing HIV in latent reservoirs, has become a strategic priority for global AIDS research. However, in early-phase HIV cure research there are ethical challenges related to the uncertainty around potential risks and the risk-benefit balance. Similar to clinical trials in other disease areas, these concerns may impact clinical trial participants' comprehension and decision making. Here we suggest attention to the terminology used to describe HIV cure research that may promote therapeutic misconception, and exploration of the decision-making influences and processes of those who accept and decline participation in HIV cure trials. These data will facilitate efforts to improve protocols and informed consent based on an understanding of participant preferences and needs.
艾滋病病毒治愈研究是一系列旨在根除或大幅减少潜伏库中艾滋病病毒的多样化研究,已成为全球艾滋病研究的战略重点。然而,在艾滋病病毒治愈研究的早期阶段,存在与潜在风险的不确定性以及风险效益平衡相关的伦理挑战。与其他疾病领域的临床试验类似,这些担忧可能会影响临床试验参与者的理解和决策。在此,我们建议关注用于描述可能会引发治疗误解的艾滋病病毒治愈研究的术语,并探索那些接受和拒绝参与艾滋病病毒治愈试验者的决策影响因素和过程。这些数据将有助于基于对参与者偏好和需求的理解来改进试验方案和知情同意书。